National Early Warning Score
Medscape Launches “Where Public Health Meets Practice” Learning Center to Translate Public Health Strategies into Patient Care
The Medscape Division of Public Health announced the launch of the "Where Public Health Meets Practice" Learning Center, a dedicated educational destination on Medscape.org. The new center serves as...
Europe Celebrates the Heart of Healthcare Decision-Making as Laboratory Medicine Professionals Take Centre Stage
Today, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) proudly marks European Laboratory Day, celebrating the professionals at the heart of healthcare decision making. Across Europe, laboratories will...
Bridging the gap: Should pharma step up as public health campaign funding declines?
With the decline in UK public health campaign funding, we have explored the unique opportunity presented to the pharmaceutical industry to step forward and do more to support the nation’s...
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination
UK government’s AMR study highlights importance of appropriate antibiotic use
The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam
UKHSA releases list of pathogens posing ‘greatest risk’ to public health
The agency has listed 24 pathogen families where preparedness efforts are most needed
NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis
Around 1,000 patients could benefit from the relugolix combination therapy every year
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment
Making an Impact at the Agents of Change Summit
Medscape Public Health is hitting the road to attend the public health conference Agents of Change. As part of their commitment to making an impact in public health, Medscape is...
AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi
More than 49,000 people are diagnosed with lung cancer in the UK each year
NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree
Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision
NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer
More than 100 patients are expected to be eligible for the treatment every year